Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 91 AL 105

The multifactorial nature of Alzheimer's disease for developing potential therapeutics

Carreiras MC, Mendes E, Perry MJ, Francisco AP, Marco-Contelles J.

Curr Top Med Chem. 2013;13(15):1745-70. doi: 10.2174/15680266113139990135.

Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment?

Rampa A, Gobbi S, Belluti F, Bisi A.

Curr Top Med Chem. 2013;13(15):1879-904. doi: 10.2174/15680266113139990143.

Natural products as sources of new lead compounds for the treatment of Alzheimer's disease

Huang L, Su T, Li X.

Curr Top Med Chem. 2013;13(15):1864-78. doi: 10.2174/15680266113139990142.

From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach

Calzà L, Baldassarro VA, Giuliani A, Lorenzini L, Fernandez M, Mangano C, Sivilia S, Alessandri M, Gusciglio M, Torricella R, Giardino L.

Curr Top Med Chem. 2013;13(15):1843-52. doi: 10.2174/15680266113139990140.

Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates

Viayna E, Sabate R, Muñoz-Torrero D.

Curr Top Med Chem. 2013;13(15):1820-42. doi: 10.2174/15680266113139990139.

Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease

Martinez A, Perez DI, Gil C.

Curr Top Med Chem. 2013;13(15):1808-19. doi: 10.2174/15680266113139990138.

The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors

Butini S, Brogi S, Novellino E, Campiani G, Ghosh AK, Brindisi M, Gemma S.

Curr Top Med Chem. 2013;13(15):1787-807. doi: 10.2174/15680266113139990137.

Multifunctional tacrine derivatives in Alzheimer's disease

Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V.

Curr Top Med Chem. 2013;13(15):1771-86. doi: 10.2174/15680266113139990136.

New approaches to the treatment of Alzheimer's disease

Rampa A, Bisi A.

Curr Top Med Chem. 2013;13(15):1743-4. doi: 10.2174/15680266113139990134.

Successes and failures for drugs in late-stage development for Alzheimer's disease

Berk C, Sabbagh MN.

Drugs Aging. 2013 Oct;30(10):783-92. doi: 10.1007/s40266-013-0108-6.

Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep

Song HR, Woo YS, Wang HR, Jun TY, Bahk WM.

Int Clin Psychopharmacol. 2013 Nov;28(6):346-8. doi: 10.1097/YIC.0b013e328364f58d.

Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies

Liu YH, Zeng F, Wang YR, Zhou HD, Giunta B, Tan J, Wang YJ.

Drug Discov Today. 2013 Dec;18(23-24):1212-20. doi: 10.1016/j.drudis.2013.07.020. Epub 2013 Aug 13.

Human Vaccines & Immunotherapeutics. Letter from the editor

Ellis R, Riedmann EM.

Hum Vaccin Immunother. 2013 Aug;9(8):1609-10. doi: 10.4161/hv.26188. Epub 2013 Aug 1.

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease

Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C.

Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):583-91. doi: 10.1177/1533317513495104.

The therapeutics of Alzheimer's disease: where we stand and where we are heading

Selkoe DJ.

Ann Neurol. 2013 Sep;74(3):328-36. doi: 10.1002/ana.24001.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias